Patient demographics and baseline disease characteristics
| Variable . | Ruxolitinib (N = 71) . |
|---|---|
| Median (range) age, y | 58 (18-73) |
| Age group, n (%) | |
| <65 y | 58 (81.7) |
| ≥65 y | 13 (18.3) |
| Female, n (%) | 36 (50.7) |
| Race, n (%) | |
| White | 66 (93.0) |
| Black | 3 (4.2) |
| Asian | 2 (2.8) |
| MAGIC aGVHD grade, n (%) | |
| II | 23 (32.4) |
| III | 34 (47.9) |
| IV | 14 (19.7) |
| Steroid-refractory criteria, n (%) | |
| Progressive GVHD after 3 d of primary treatment | 19 (26.8) |
| GVHD not improved after 7 d of primary treatment | 30 (42.3) |
| Previously began CS therapy at a lower dose, but developed new GVHD in another organ system | 8 (11.3) |
| Unable to tolerate CS taper | 14 (19.7) |
| Median (range) prior exposure to corticosteroids, d | 15 (3-285) |
| Underlying malignancy, n (%) | |
| Acute myeloid leukemia | 20 (28.2) |
| Myelodysplastic syndrome | 20 (28.2) |
| Lymphoma | 9 (12.7) |
| Acute lymphoblastic leukemia | 8 (11.3) |
| Chronic lymphocytic leukemia | 3 (4.2) |
| Myelofibrosis/myeloproliferative neoplasm | 2 (2.8) |
| Multiple myeloma | 2 (2.8) |
| Other | 7 (9.9) |
| Donor type, n (%) | |
| Matched unrelated donor | 27 (38.0) |
| Matched related donor | 18 (25.4) |
| Mismatched related donor | 11 (15.5) |
| Mismatched unrelated donor | 10 (14.1) |
| Other | 5 (7.0) |
| Conditioning regimen, n (%) | |
| Nonmyeloablative | 36 (50.7) |
| Myeloablative | 31 (43.7) |
| Missing | 4 (5.6) |
| Prior lines of therapy (other than corticosteroids), n (%) | |
| 1 | 59 (83.1) |
| >1 | 12 (16.9) |
| Graft type, n (%) | |
| Peripheral blood stem cells | 57 (80.3) |
| Bone marrow | 13 (18.3) |
| Umbilical cord blood | 1 (1.4) |
| CMV serostatus, n (%)* | |
| Donor-positive/recipient-positive | 24 (33.8) |
| Donor-positive/recipient-negative | 7 (9.9) |
| Donor-negative/recipient-positive | 16 (22.5) |
| Donor-negative/recipient-negative | 23 (32.4) |
| Missing | 1 (1.4) |
| Variable . | Ruxolitinib (N = 71) . |
|---|---|
| Median (range) age, y | 58 (18-73) |
| Age group, n (%) | |
| <65 y | 58 (81.7) |
| ≥65 y | 13 (18.3) |
| Female, n (%) | 36 (50.7) |
| Race, n (%) | |
| White | 66 (93.0) |
| Black | 3 (4.2) |
| Asian | 2 (2.8) |
| MAGIC aGVHD grade, n (%) | |
| II | 23 (32.4) |
| III | 34 (47.9) |
| IV | 14 (19.7) |
| Steroid-refractory criteria, n (%) | |
| Progressive GVHD after 3 d of primary treatment | 19 (26.8) |
| GVHD not improved after 7 d of primary treatment | 30 (42.3) |
| Previously began CS therapy at a lower dose, but developed new GVHD in another organ system | 8 (11.3) |
| Unable to tolerate CS taper | 14 (19.7) |
| Median (range) prior exposure to corticosteroids, d | 15 (3-285) |
| Underlying malignancy, n (%) | |
| Acute myeloid leukemia | 20 (28.2) |
| Myelodysplastic syndrome | 20 (28.2) |
| Lymphoma | 9 (12.7) |
| Acute lymphoblastic leukemia | 8 (11.3) |
| Chronic lymphocytic leukemia | 3 (4.2) |
| Myelofibrosis/myeloproliferative neoplasm | 2 (2.8) |
| Multiple myeloma | 2 (2.8) |
| Other | 7 (9.9) |
| Donor type, n (%) | |
| Matched unrelated donor | 27 (38.0) |
| Matched related donor | 18 (25.4) |
| Mismatched related donor | 11 (15.5) |
| Mismatched unrelated donor | 10 (14.1) |
| Other | 5 (7.0) |
| Conditioning regimen, n (%) | |
| Nonmyeloablative | 36 (50.7) |
| Myeloablative | 31 (43.7) |
| Missing | 4 (5.6) |
| Prior lines of therapy (other than corticosteroids), n (%) | |
| 1 | 59 (83.1) |
| >1 | 12 (16.9) |
| Graft type, n (%) | |
| Peripheral blood stem cells | 57 (80.3) |
| Bone marrow | 13 (18.3) |
| Umbilical cord blood | 1 (1.4) |
| CMV serostatus, n (%)* | |
| Donor-positive/recipient-positive | 24 (33.8) |
| Donor-positive/recipient-negative | 7 (9.9) |
| Donor-negative/recipient-positive | 16 (22.5) |
| Donor-negative/recipient-negative | 23 (32.4) |
| Missing | 1 (1.4) |
CS, corticosteroid.
Donor serostatus was missing from 1 patient (patient was positive).